Roger Marshall Stock Trades: The Doctor Senator's Healthcare Portfolio

Who is Roger Marshall?

Roger Marshall (R-KS) is a Republican senator from Kansas, elected in 2020. Before politics he practiced obstetrics and gynecology in Great Bend, Kansas, for roughly 25 years — delivering thousands of babies and running his own medical practice. He served in the Kansas House and later in the U.S. House of Representatives (2017–2021) before winning his Senate seat.

He currently serves on three Senate committees: Health, Education, Labor, and Pensions (HELP), Agriculture, Nutrition, and Forestry, and Banking, Housing, and Urban Affairs. The HELP Committee is the most consequential of the three for anyone interested in his trading activity — it has direct jurisdiction over FDA authority, pharmaceutical pricing, Medicare and Medicaid policy, and public health legislation.

Marshall is also one of very few practicing physicians who have served in the U.S. Senate in recent decades. That background is relevant not just as biography — it means he carries technical domain expertise into a committee role that already confers significant regulatory insight. You can see his full disclosed trading history on the Roger Marshall Capitol Gains profile.

The three-layer conflict question

Most congressional trading conflict-of-interest analysis focuses on one layer: a senator sits on a committee with regulatory power over an industry, and they happen to trade in that industry. That single layer is why Tommy Tuberville's Armed Services seat and defense stock trading attracted attention, and why Rand Paul's HELP Committee role and healthcare trades draw scrutiny.

Roger Marshall is unusual because the conflict-of-interest analysis has three distinct layers stacked on top of each other:

1. Medical expertise. Two and a half decades of clinical practice in obstetrics and gynecology means Marshall has domain knowledge that goes beyond what most senators — lawyers, businesspeople, career politicians — bring to healthcare sector investing. He can read a clinical trial outcome and understand its significance faster than almost anyone else in the chamber.
2. HELP Committee access. As a HELP Committee member, Marshall attends closed-door briefings from FDA officials, pharmaceutical executives, and public health administrators. He receives testimony and staff memos before they are public. He has advance knowledge of which drug-pricing bills are moving and which will stall.
3. Legislative voting power. Marshall does not merely observe healthcare regulation — he votes on it. His votes on drug pricing legislation, FDA reauthorization, and Medicare policy directly affect the valuation of pharmaceutical and biotech companies. And he also holds positions in those same companies.

No individual layer makes any specific trade illegal or improper — the STOCK Act prohibits trading on material non-public information, and no published evidence has alleged that Marshall has done so. But the structural overlap between his professional background, his committee role, and his disclosed portfolio is unusually dense.

What the STOCK Act filings show

Marshall's Periodic Transaction Reports, filed under the STOCK Act, document trades in a range of equities including healthcare and pharmaceutical names. His disclosures show activity across both buy and sell transactions, at various disclosure values within the STOCK Act's tiered range system ($1,001–$15,000; $15,001–$50,000; $50,001–$100,000; $100,001–$250,000; and above).

Transparency watchdogs and financial journalists have scrutinized his filings specifically in the context of his HELP Committee work — checking whether disclosed trades in pharmaceutical or biotech companies occurred around the timing of relevant committee activity, hearings, or major regulatory announcements.

Marshall has also attracted attention for the timing of some disclosures. The STOCK Act requires senators to file within 45 days of a transaction. Late filings — even when accidental — attract press attention and are the basis for CREW (Citizens for Responsibility and Ethics in Washington) complaints. Marshall, like many senators, has had disclosures flagged for filing timing.

The full Roger Marshall trade history on Capitol Gains is updated in real time as new STOCK Act filings arrive.

Drug pricing legislation and portfolio overlap

The HELP Committee's most consequential recent work has been on pharmaceutical pricing. The Inflation Reduction Act of 2022 included provisions allowing Medicare to negotiate drug prices directly with manufacturers — the most significant change to pharmaceutical pricing policy in decades. The HELP Committee and the Senate Finance Committee were central to that debate.

Marshall opposed the drug pricing provisions of the IRA, arguing they would chill pharmaceutical innovation. That policy position is coherent and shared by many in the Republican caucus. But it is also a position that, if successful, benefits pharmaceutical companies whose stock prices are sensitive to drug-pricing regulation.

This is the core of the structural conflict concern: it is not necessarily that a senator is trading on inside information. It is that a senator's policy votes and a senator's investment positions can point in the same direction — and the public has no way of knowing which is driving which.

Marshall's position on the trading ban

Marshall has not been among the leading voices for a congressional trading ban. He has not co-sponsored the Stop Insider Trading Act or the Restore Trust in Congress Act — the two primary ban bills advancing in 2026 with bipartisan support. His public statements on congressional trading have generally emphasized transparency (STOCK Act disclosure) as the appropriate mechanism, rather than outright prohibition.

That position is consistent with the majority of Republican senators, though the 2026 momentum behind both bills — driven by growing public frustration after a series of high-profile trading stories — has shifted some Republicans toward supporting a ban. As of this writing, neither bill has reached the Senate floor for a vote.

The Capitol Gains congressional trading ban page tracks the current status of all active ban legislation and which senators are sponsoring or opposing each bill.

How does he compare to other trading senators?

Marshall is not the highest-volume trader in the Senate. By raw disclosure count, senators like Tommy Tuberville significantly outpace him. But volume alone is not the most relevant metric for evaluating the conflict-of-interest question — the relevant question is whether the sectors being traded overlap with the senator's committee jurisdiction and professional background.

On that dimension, Marshall's profile is unusually concentrated. A defense lawyer trading defense stocks while on Armed Services raises one flag. A physician trading pharma and biotech while on HELP, with a long career of clinical expertise in the underlying science, raises a different kind of question about informational advantage — one that does not require any allegation of wrongdoing to be worth scrutinizing.

The Capitol Gains senator leaderboard ranks all active trading senators by their return performance relative to the S&P 500 — which puts the raw numbers in context against the market baseline.

Why Roger Marshall matters for the reform debate

The congressional trading debate often gets framed around the most extreme cases — senators with hundreds of disclosed trades, or trades that look suspiciously timed around market-moving votes. Marshall is a different kind of case study: the question his profile raises is not about volume or suspicious timing, but about whether domain expertise layered on top of committee access creates a structural advantage that the STOCK Act's disclosure mechanism was never designed to address.

A senator who is also a physician, sitting on the committee that regulates the pharmaceutical industry, while trading in pharmaceutical equities, is a test case for a version of the reform argument that goes beyond "trading on tips from a closed-door briefing." It raises the question of whether professional expertise itself — combined with committee access — constitutes an unfair advantage that passive disclosure does not neutralize.

That is a more philosophically difficult question than the one the STOCK Act was designed to answer. It is also the question the trading ban debate is increasingly being asked to address.

This article is for informational purposes only. All trade data is sourced from public STOCK Act PTR filings available via the US Senate Financial Disclosure portal. Inclusion of any senator's name does not imply wrongdoing or illegal conduct. Nothing here constitutes legal or financial advice.